세계의 안티트롬빈 시장 : 제제별, 공급원별, 유형별, 경로별, 용도별 - 예측(2025-2030년)

The Antithrombin Market was valued at USD 796.09 million in 2023, expected to reach USD 876.87 million in 2024, and is projected to grow at a CAGR of 10.24%, to USD 1,575.32 million by 2030.

Antithrombin is a vital plasma protein that helps regulate blood coagulation by inhibiting thrombin and other enzymes involved in the clotting process. The necessity of antithrombin arises from its critical role in preventing abnormal clot formation, thereby mitigating risks associated with conditions like deep vein thrombosis, pulmonary embolism, and other coagulation disorders. It finds application primarily in therapeutics, particularly in surgeries involving cardiopulmonary bypass and during heparin therapy, where it helps to regulate anticoagulation. The end-use scope primarily includes healthcare facilities, researchers in hematology, and pharmaceutical companies focusing on anticoagulant therapies. The antithrombin market is influenced by several growth factors, including the increasing prevalence of coagulation disorders and advancements in biotechnology that facilitate the development of recombinant protein drugs. There is a growing potential in expanding its use in treating genetic antithrombin deficiency and developing novel formulations with enhanced efficacy and delivery. Opportunities exist in emerging markets with rising healthcare expenditures and the deployment of innovative diagnostics for blood disorders. However, the market faces limitations such as high production costs and stringent regulatory requirements for biologics, which can delay product approvals. The complexity of manufacturing recombinant proteins also poses significant challenges. The industry could benefit from research into synthetic biology to lower production costs, enhance yield, and create more stable antithrombin formulations. Innovations in drug delivery systems that improve the bioavailability and stability of antithrombin could also drive market growth. The nature of the antithrombin market is competitive, with key players focusing on strategic partnerships and research collaborations to expand their product portfolios. Overall, future market development hinges on overcoming regulatory and economic challenges while harnessing technological advancements to develop cost-effective and therapeutically potent antithrombin products.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Antithrombin Market

The Antithrombin Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Growing occurrence of antithrombin deficiency and increased bleeding during surgeries
  • Utilization of rapid diagnostic tests and need for antithrombin
  • Increasing awareness of the thrombotic disease among consumers
• Market Restraints
  • Capital-intensive production of antithrombin
• Market Opportunities
  • Rising adoption of natural agents in antithrombins
  • Technological advancements in the development of cost-effective procedures in the production of antithrombin
• Market Challenges
  • Limitations of lab testing of antithrombin deficiency

Porter's Five Forces: A Strategic Tool for Navigating the Antithrombin Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Antithrombin Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Antithrombin Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Antithrombin Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Antithrombin Market

A detailed market share analysis in the Antithrombin Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Antithrombin Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Antithrombin Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Antithrombin Market

A strategic analysis of the Antithrombin Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Antithrombin Market, highlighting leading vendors and their innovative profiles. These include Bio-Techne Corporation, BioPharm Laboratories, LLC, CSL Limited, Diapharma Group, Inc., European Medicines Agency, Genesis BioPharma, Grifols, S.A., Kedrion S.p.A., Lee Biosolutions, Inc., LFB USA, Inc., Merck KGaA, Octapharma AG, Scripps Laboratories, Inc., Siemens AG, SK Plasma, Takeda Pharmaceutical Company Limited, Thermo Fisher Scientific Inc., and WebMD, LLC.

Market Segmentation & Coverage

This research report categorizes the Antithrombin Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Formulation, market is studied across Liquid and Lyophilized.
• Based on Source, market is studied across Goat Milk and Human.
• Based on Type, market is studied across Anticoagulant, Antiplatelet, and Thrombolytic Drugs.
• Based on Route, market is studied across Oral and Parenteral.
• Based on Application, market is studied across Diagnostics, Research, and Therapeutics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing occurrence of antithrombin deficiency and increased bleeding during surgeries
    • 5.1.1.2. Utilization of rapid diagnostic tests and need for antithrombin
    • 5.1.1.3. Increasing awareness of the thrombotic disease among consumers
  • 5.1.2. Restraints
    • 5.1.2.1. Capital-intensive production of antithrombin
  • 5.1.3. Opportunities
    • 5.1.3.1. Rising adoption of natural agents in antithrombins
    • 5.1.3.2. Technological advancements in the development of cost-effective procedures in the production of antithrombin
  • 5.1.4. Challenges
    • 5.1.4.1. Limitations of lab testing of antithrombin deficiency
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Antithrombin Market, by Formulation

• 6.1. Introduction
• 6.2. Liquid
• 6.3. Lyophilized

7. Antithrombin Market, by Source

• 7.1. Introduction
• 7.2. Goat Milk
• 7.3. Human

8. Antithrombin Market, by Type

• 8.1. Introduction
• 8.2. Anticoagulant
• 8.3. Antiplatelet
• 8.4. Thrombolytic Drugs

9. Antithrombin Market, by Route

• 9.1. Introduction
• 9.2. Oral
• 9.3. Parenteral

10. Antithrombin Market, by Application

• 10.1. Introduction
• 10.2. Diagnostics
• 10.3. Research
• 10.4. Therapeutics

11. Americas Antithrombin Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Antithrombin Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Antithrombin Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
• 14.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Bio-Techne Corporation
• 2. BioPharm Laboratories, LLC
• 3. CSL Limited
• 4. Diapharma Group, Inc.
• 5. European Medicines Agency
• 6. Genesis BioPharma
• 7. Grifols, S.A.
• 8. Kedrion S.p.A.
• 9. Lee Biosolutions, Inc.
• 10. LFB USA, Inc.
• 11. Merck KGaA
• 12. Octapharma AG
• 13. Scripps Laboratories, Inc.
• 14. Siemens AG
• 15. SK Plasma
• 16. Takeda Pharmaceutical Company Limited
• 17. Thermo Fisher Scientific Inc.
• 18. WebMD, LLC